NZ793447A - Humanized rodents that express heavy chains containing vl domains - Google Patents

Humanized rodents that express heavy chains containing vl domains

Info

Publication number
NZ793447A
NZ793447A NZ793447A NZ79344713A NZ793447A NZ 793447 A NZ793447 A NZ 793447A NZ 793447 A NZ793447 A NZ 793447A NZ 79344713 A NZ79344713 A NZ 79344713A NZ 793447 A NZ793447 A NZ 793447A
Authority
NZ
New Zealand
Prior art keywords
human
domains
heavy chains
chains containing
express heavy
Prior art date
Application number
NZ793447A
Other languages
English (en)
Inventor
Lynn Macdonald
Sean Stevens
Cagan Gurer
Karolina Meagher
Andrew Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority to NZ810648A priority Critical patent/NZ810648A/en
Publication of NZ793447A publication Critical patent/NZ793447A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Housing For Livestock And Birds (AREA)
  • Central Heating Systems (AREA)
NZ793447A 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains NZ793447A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ810648A NZ810648A (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261593463P 2012-02-01 2012-02-01
US201261677538P 2012-07-31 2012-07-31
NZ734504A NZ734504A (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Publications (1)

Publication Number Publication Date
NZ793447A true NZ793447A (en) 2024-05-31

Family

ID=47714588

Family Applications (5)

Application Number Title Priority Date Filing Date
NZ793447A NZ793447A (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains
NZ734504A NZ734504A (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains
NZ810648A NZ810648A (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains
NZ719228A NZ719228A (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containg vl domains
NZ627977A NZ627977A (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Family Applications After (4)

Application Number Title Priority Date Filing Date
NZ734504A NZ734504A (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains
NZ810648A NZ810648A (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains
NZ719228A NZ719228A (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containg vl domains
NZ627977A NZ627977A (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Country Status (26)

Country Link
US (3) US20130212719A1 (enExample)
EP (3) EP3597038B1 (enExample)
JP (6) JP2015505477A (enExample)
KR (2) KR20190006029A (enExample)
CN (2) CN104202971B (enExample)
AU (3) AU2013204758B2 (enExample)
BR (1) BR112014018843B1 (enExample)
CA (1) CA2863175A1 (enExample)
CY (2) CY1122419T1 (enExample)
DK (2) DK3597038T3 (enExample)
ES (2) ES2753774T3 (enExample)
HR (2) HRP20192218T1 (enExample)
HU (2) HUE055610T2 (enExample)
IL (3) IL233827A0 (enExample)
LT (2) LT3597038T (enExample)
ME (1) ME03611B (enExample)
MX (2) MX2020003491A (enExample)
NZ (5) NZ793447A (enExample)
PL (2) PL3597038T3 (enExample)
PT (2) PT2809150T (enExample)
RS (2) RS62023B1 (enExample)
RU (2) RU2770016C2 (enExample)
SG (3) SG10201606256TA (enExample)
SI (2) SI3597038T1 (enExample)
SM (2) SMT202100401T1 (enExample)
WO (1) WO2013116609A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
PT2564695E (pt) 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
RU2612903C2 (ru) 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
RS66089B1 (sr) 2011-08-05 2024-11-29 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
EP3839049A3 (en) 2011-09-19 2021-10-20 Kymab Limited Antibodies, variable domains & chains tailored for human use
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SI2793567T1 (sl) 2011-12-20 2019-05-31 Regeneron Pharmaceuticals, Inc. Humanizirane lahkoverižne miši
HRP20192218T1 (hr) * 2012-02-01 2020-03-06 Regeneron Pharmaceuticals, Inc. Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JP2015519076A (ja) 2012-06-12 2015-07-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 限定された免疫グロブリン重鎖遺伝子座を有するヒト化非ヒト動物
CN105734081A (zh) 2013-02-20 2016-07-06 瑞泽恩制药公司 具有修饰的免疫球蛋白重链序列的非人类动物
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
EP3895528A1 (en) 2014-03-21 2021-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CN106164092A (zh) 2014-03-21 2016-11-23 瑞泽恩制药公司 表现不同结合特征的vl抗原结合蛋白
JP2018508224A (ja) * 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
EP4335918A3 (en) * 2015-04-03 2024-04-17 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
CN109072191B (zh) * 2016-04-04 2024-03-22 苏黎世联邦理工学院 用于蛋白生产和文库产生的哺乳动物细胞系
CN109475109B (zh) 2016-05-20 2021-10-29 瑞泽恩制药公司 用于使用多个引导rna来破坏免疫耐受性的方法
CN110719732B (zh) * 2017-03-30 2022-11-18 犹他州立大学 表达蜘蛛丝的转基因蚕
PL4140297T3 (pl) * 2017-12-05 2025-08-25 Regeneron Pharmaceuticals, Inc. Myszy mające zmodyfikowany sposobami inżynierii łańcuch lekki lambda immunoglobuliny i ich zastosowania
US20210051929A1 (en) * 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
IL318469A (en) * 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
JP2023540808A (ja) 2020-09-11 2023-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗原特異的抗体の同定及び産生
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CN114645042A (zh) * 2020-12-18 2022-06-21 中国食品药品检定研究院 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法
CN114196626A (zh) * 2022-02-16 2022-03-18 北京国卫生物科技有限公司 脐带间充质干细胞及其分离培养扩增方法
CN118339300A (zh) * 2024-01-02 2024-07-12 江苏集萃药康生物科技股份有限公司 产生人源化抗体的动物模型及其构建方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
CA2422155A1 (en) * 2000-08-03 2002-02-14 Wim Van Schooten Production of humanized antibodies in transgenic animals
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
EP1458852B1 (en) 2001-12-21 2011-03-09 ThromboGenics N.V. Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
WO2003081993A2 (en) * 2002-03-22 2003-10-09 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
EP1644417B1 (en) * 2003-07-15 2014-04-30 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
DK2767161T3 (en) 2004-10-19 2018-05-07 Regeneron Pharma Method of generating an animal homozygous for genetic modification
WO2006047367A2 (en) * 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglubolin expression in non-human transgenic animals
JP5514539B2 (ja) * 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
ATE536374T1 (de) * 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
US8426565B2 (en) * 2007-08-30 2013-04-23 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
TWI464262B (zh) * 2007-09-26 2014-12-11 中外製藥股份有限公司 抗體固定區的變異
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
HUE057994T2 (hu) * 2008-06-27 2022-06-28 Merus Nv Antitesttermelõ, transzgenikus, egérfélékhez tartozó állat
AU2009287165A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
WO2010091182A2 (en) * 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
PT2564695E (pt) * 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
CN103228130B (zh) * 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
RU2612903C2 (ru) * 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
PL4067496T3 (pl) * 2011-02-25 2023-07-31 Regeneron Pharmaceuticals, Inc. Myszy adam6
RS66089B1 (sr) * 2011-08-05 2024-11-29 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
SI2793567T1 (sl) * 2011-12-20 2019-05-31 Regeneron Pharmaceuticals, Inc. Humanizirane lahkoverižne miši
HRP20192218T1 (hr) * 2012-02-01 2020-03-06 Regeneron Pharmaceuticals, Inc. Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene
JP2015519076A (ja) * 2012-06-12 2015-07-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 限定された免疫グロブリン重鎖遺伝子座を有するヒト化非ヒト動物
SMT202000558T1 (it) * 2016-11-04 2020-11-10 Regeneron Pharma Animali non umani aventi un locus di catena leggera di immunoglobulina lambda ingegnerizzata

Also Published As

Publication number Publication date
RU2014133653A (ru) 2016-03-20
JP2023014242A (ja) 2023-01-26
EP3597038B1 (en) 2021-04-21
IL261280A (en) 2018-10-31
SMT202100401T1 (it) 2021-09-14
EP3912465A1 (en) 2021-11-24
JP7525579B2 (ja) 2024-07-30
ES2870703T3 (es) 2021-10-27
KR20190006029A (ko) 2019-01-16
NZ810648A (en) 2025-11-28
JP7187615B2 (ja) 2022-12-12
IL233827A0 (en) 2014-09-30
IL268675B (en) 2020-11-30
HUE046744T2 (hu) 2020-03-30
SMT201900685T1 (it) 2020-01-14
US20130212719A1 (en) 2013-08-15
RU2664185C2 (ru) 2018-08-15
JP2023168590A (ja) 2023-11-24
AU2015246154B2 (en) 2017-11-23
AU2017251848A1 (en) 2017-11-16
LT3597038T (lt) 2021-05-25
JP2015505477A (ja) 2015-02-23
CN104202971B (zh) 2016-07-06
EP2809150A1 (en) 2014-12-10
RU2770016C2 (ru) 2022-04-14
MX373286B (es) 2020-05-20
LT2809150T (lt) 2019-10-25
CN106117364A (zh) 2016-11-16
BR112014018843B1 (pt) 2024-02-20
JP6942757B2 (ja) 2021-09-29
HUE055610T2 (hu) 2021-12-28
BR112014018843A8 (pt) 2019-01-29
IL268675A (en) 2019-10-31
RS59699B1 (sr) 2020-01-31
HK1202771A1 (en) 2015-10-09
NZ734504A (en) 2022-10-28
SG10201913428QA (en) 2020-03-30
IL261280B (en) 2019-08-29
DK3597038T3 (da) 2021-06-28
SG10201606256TA (en) 2016-09-29
CN104202971A (zh) 2014-12-10
AU2013204758B2 (en) 2015-07-23
SI2809150T1 (sl) 2019-11-29
KR20140123983A (ko) 2014-10-23
EP3597038A1 (en) 2020-01-22
PT2809150T (pt) 2019-12-09
AU2013204758A1 (en) 2013-08-15
CY1122419T1 (el) 2021-01-27
US20170094955A1 (en) 2017-04-06
PL2809150T3 (pl) 2020-04-30
US20210368751A1 (en) 2021-12-02
JP6698718B2 (ja) 2020-05-27
CA2863175A1 (en) 2013-08-08
HRP20210987T1 (hr) 2021-09-17
JP2018075041A (ja) 2018-05-17
ME03611B (me) 2020-07-20
AU2015246154A1 (en) 2015-11-12
JP2019170395A (ja) 2019-10-10
CY1124361T1 (el) 2022-07-22
NZ719228A (en) 2022-08-26
EP2809150B1 (en) 2019-09-18
DK2809150T3 (da) 2019-12-09
AU2017251848B2 (en) 2020-02-20
SI3597038T1 (sl) 2021-07-30
PT3597038T (pt) 2021-05-10
ES2753774T3 (es) 2020-04-14
JP2021137030A (ja) 2021-09-16
HRP20192218T1 (hr) 2020-03-06
SG11201404477YA (en) 2014-08-28
RS62023B1 (sr) 2021-07-30
BR112014018843A2 (pt) 2017-07-04
CN106117364B (zh) 2021-08-31
MX2020003491A (es) 2022-10-25
PL3597038T3 (pl) 2021-11-08
MX2019002517A (es) 2019-06-17
RU2018122695A (ru) 2019-03-06
WO2013116609A1 (en) 2013-08-08
RU2018122695A3 (enExample) 2021-10-06
NZ627977A (en) 2016-06-24

Similar Documents

Publication Publication Date Title
NZ734504A (en) Humanized rodents that express heavy chains containing vl domains
MX379533B (es) Ratones de cadena ligera universal humanizados.
MX2021000829A (es) Animales no humanos humanizados con loci de cadena pesada de inmunoglobulina restringidos.
CY1122036T1 (el) Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα
MY178882A (en) Non-human animals with modified immunoglobulin heavy chain sequences
MX2020005830A (es) Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos.
FI2738258T4 (fi) ADAM6-hiiriä
MX2021010556A (es) Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.
EA201171148A1 (ru) Антитело-антагонист, специфичное для гетеродимера альфа-4-бета-7
NZ629639A (en) Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
BR112016021572A2 (pt) Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
MY173936A (en) Humanized light chain mice field of invention
BR112016005912A2 (pt) sequência de ácido nucleico de cadeia leve de imunoglobulina recombinante, animal não humano geneticamente modificado, métodos para gerar um anticorpo e uma proteína de ligação e para produzir um animal não humano, célula ou tecido, vetor de alvejamento, proteína de ligação, e, ácido nucleico
MX2021014818A (es) Anticuerpos monoclonales anti-cd303.
EA201990959A1 (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
MX2015012539A (es) Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina.
MX2016014504A (es) Animales c5 y c3 humanizados.
MX2015012540A (es) Ratón de cadena ligera común.
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
MX2014012977A (es) Anticuerpos anti-cd22.
BR112016021679A2 (pt) proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
EA201690383A1 (ru) НОВЫЕ АНТИТЕЛА К FC-γ-РЕЦЕПТОРУ IIB И ИХ ПРИМЕНЕНИЯ
EP3548054A4 (en) ANTI-DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST EBOLA VIRUS
HK1231692A1 (en) Non-human animals that make single domain binding proteins

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 01 FEB 2026 BY FB RICE PTY LTD

Effective date: 20241010